Concepedia

Yizhen Lai

YL

Statistics

Publications

4

Citations

86

H-Index

4

Active since

2020

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Pennsylvania

BresMed

Yizhen Lai is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in urology, outcomes research, and surgical oncology.

Top concepts

Publications per year

2020–2023

4

Publications

4

Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1–positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States

Oliver Hale, K. Patterson, Yizhen Lai et al. · Clinical Genitourinary Cancer · 2020 · 28 citations

Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States

Raquel Aguiar‐Ibáñez, Chloë Hardern, Frank van Hees et al. · Journal of Medical Economics · 2022 · 27 citations · Full text

The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States

Rachael Louise Slater, Yizhen Lai, Yichen Zhong et al. · Journal of Medical Economics · 2020 · 18 citations · Full text

Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States

Yizhen Lai, Arielle G. Bensimon, Emily Gao et al. · Clinical Genitourinary Cancer · 2023 · 13 citations

, , +8

1–4 of 4